Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SIPA1 expression in breast cancer patient

ABSTRACT: To study the expression of SIPA1 in patients with metastatic triple-negative breast cancer, we obtained a subcutaneous metastatic sample from a patient with stage III triple-negative breast cancer and performed single-cell transcriptome sequencing

ORGANISM(S): Homo sapiens

PROVIDER: GSE221731 | GEO | 2022/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Role of SIPA1 in chemotherapy resistance in breast cancer cells

Project description:SIPA1 is a potential transcriptional modulator of tumor metastasis and recurrence. Here we showed that the breast cancer patients with higher SIPA1 expression have a higher relapse rate and worse prognosis, especially for triple-negative breast cancer (TNBC) patients. Moreover, SIPA1 expression was found positively correlated with relapse of breast cancer patients receiving adjuvant chemotherapy. In a TNBC cell line MDA-MB-231, we identified the possible tumorigenesis and metastasis processes regulated by SIPA1, and demonstrated that SIPA1 promoted cancer stem-like feature to form tumourspheres. Tumoursphere-formed MDA-MB-231 cells were shown to be resistant to epirubicin. Then we confirmed that SIPA1 could particularly activate the CD44 promoter and upregulate CD44 expression. Furthermore, SIPA1 could promote ABCB1 expression and strengthen chemoresistance of MDA-MB-231 cells to epirubicin. In conclusion, SIPA1 is a risk factor for highly-relapse in TNBC patients and a transcriptional regulator to maintain cancer stem-like features and promote chemoresistance in breast cancer cells.

2018-12-25 | GSE124344 | GEO

SIPA1 expression in breast cancer patient

Project description:SIPA1 expression in breast cancer patient

| PRJNA915622 | ENA

Exploring mechanism the transcription factor SIPA1 promote the progression of triple-negative breast cancer

Project description:Exploring mechanism the transcription factor SIPA1 promote the progression of triple-negative breast cancer

| PRJNA915947 | ENA

SIPA1 Functions as a Transcription Regulator to Sustain Progression of Triple-Negative Breast Cancer

Project description:SIPA1 Functions as a Transcription Regulator to Sustain Progression of Triple-Negative Breast Cancer

| PRJNA915946 | ENA

Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer

Project description:To define the molecular regulators of metastasis of triple-negative breast cancer, we conducted a rigorous characterization of four populations of MDA-MB-231 human triple-negative breast cancer cells that display a range of intrinsic spontaneous metastatic capacities in immuno-deficient mice, from non-metastatic to highly metastatic to lung, liver, spleen and spine. PAT-Seq gene expression profiling of primary tumor cells identified the fibroblast growth factor homologous factor, FGF13, as a candidate metastatic virulence gene highly upregulated in aggressively metastatic MDA-MB-231HM tumors.

2018-03-13 | GSE111705 | GEO

Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer.

Project description:To define the molecular regulators of metastasis of triple-negative breast cancer, we conducted a rigorous characterization of four isogenic populations of MDA-MB-231 human triple-negative breast cancer cells that display a range of intrinsic spontaneous metastatic capacities in immuno-deficient mice, from non-metastatic to highly metastatic to lung, liver, spleen and spine. PAT-Seq gene expression profiling of primary tumor cells identified the fibroblast growth factor homologous factor, FGF13, as a candidate metastatic virulence gene highly upregulated in aggressively metastatic MDA-MB-231HM tumors.

2018-02-01 | GSE101745 | GEO

Role of SIPA1 in chemotherapy resistance in breast cancer cells

Project description:Role of SIPA1 in chemotherapy resistance in breast cancer cells

| PRJNA511676 | ENA

NF-kB associated markers of PD-1 immunotherapy response in early and metastatic triple negative breast cancer

Project description:NF-kB associated markers of PD-1 immunotherapy response in early and metastatic triple negative breast cancer

2024-10-30 | GSE279896 | GEO

Proteomic study of triple negative breast cancer cell lines at different tumorigenic stages reveals a divergent reprogramming metabolism

Project description:Breast cancer is the leading type of cancer. The triple negative is the most aggressive type of breast cancer, as it is resistant to several treatments as hormone based, for example. Cell metabolism is altered in cancer cells as they favor anaerobic pathways to produce energy in a faster pace and in accordance with the hypoxic environments found inside tumor mass, which is known as the Warburg effect. In this study, we sought to investigate the molecular mechanisms behind the different cell phenotypes during tumorigenesis. To pursue this goal, we employed proteomics in four types of cells; the non-tumorigenic epithelial cell MCF-10A, two triple negative breast cancer originated from primary tumor sites (MGSO-3 and MACL-1), and the metastatic tumor cell line MDA-231-MD. Our proteomic data shown that most proteins associated with the TCA cycle and oxidative phosphorylation (aerobic metabolic phase) were upregulated in primary cells while downregulated in metastatic cell, in line with a negative regulation of the Warburg effect for the primarily cells. We also shown that these cells have lower mitochondria density and upregulation of pro-apoptotic proteins when compared with metastatic cells. Molecular differences highlighted in this study may assist the scientific community in developing new protocols to treat the triple negative breast cancer.

2022-06-07 | PXD028400 | Pride

Shin_2018_EGFR-PYK2-c-Met interaction network_model

Project description:Systems modelling of the EGFR-PYK2-c-Met interaction network predicted and prioritized synergistic drug combinations for Triple-negative breast cancer

2024-09-02 | BIOMD0000000826 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data